Deoxyribonucleic acid fragments containing the structural genes for several trimethoprim-resistant dihydrofolate reductases from naturally occurring plasmids were inserted into small cloning vehicles. The genetic expression of these hybrid plasmids was studied in purified Escherichia coli minicells. The type I dihydrofolate reductase, encoded by plasmid R483 and residing within transposon 7 (Tn7), had a subunit molecular weight of 18,000. The type II dihydrofolate reductase, specified by plasmid R67, had a subunit molecular weight of 9,000. These two enzymes were antigenically distinct in that anti-type II dihydrofolate reductase (R67) antibody did not cross-react with the type I (R483) protein. The trimethoprim-resistant reductase specified by plasmid R388 had a subunit molecular weight of about 10,500 and was immunologically related to the type II (R67) enzyme. A 9,000 subunit of the dihydrofolate encoded by the transposition element Tn4O2 was also antigenically related to the R67 reductase.
R-plasmid-mediated trimethoprim resistance was first described in clinical isolates of Escherichia coli and Klebsiella aerogenes (10) . The mechanism of plasmid-associated trimethoprim resistance involves the synthesis of novel dihydrofolate reductases (DHFRs) which are highly resistant to trimethoprim; hence, the target site rather than the antibacterial agent is modified (2, 21) . It has recently been demonstrated that R-plasmid-specified DHFRs can be separated into two broad classes based on different levels of sensitivity to trimethopri.m and other related antifolate compounds (19) . The so-called type I reductase (encoded by plasmid R483) has a 50% inhibitory concentration for trimethoprim several thousand-fold higher than that required to inhibit the E. coli chromosomal DHFR. The type II enzyme (encoded by plasmid R67) is for all practical purposes completely insensitive to trinethoprim, having 50% inhibitory concentrations several hundred-fold higher than those for the type I reductases.
Both types of plasmid-encoded enzymes show little difference from the chromosomal reductase in the binding of NADPH and dihydrofolate, and both resistant enzymes have molecular weights of about 35,000, approximately twice the size of the trimethoprim-sensitive, chromosomal reductases (19) . Hence the chromosomal and plasmid-specified enzymes appear to be quite distinct from one another on the basis of molecular weight and enzyme characteristics. These observations lead to questions regarding the evolutionary origin(s) of the trimethoprim-resistant reductases as well as the relationships of the different plasmid-encoded enzymes to one another and to the trimethoprim-sensitive chromosomal enzyme. Our approach to this question has been to isolate the DNA fragments containing the structural genes for both type I and II reductases, insert them into appropriate cloning vehicles, and then study the genetic expression of these genes in an E. coli minicell system.
MATERIALS AND METHODS
Bacterial strains and plasmids. E. coli K-12 strain DS410 (minA minB), which produces minicells, has been described (5). To construct the hybrid plasmids shown in Fig. 1 , we used conventional molecular cloning procedures (13) with some modifications (11). 
FLING AND ELWELL
Hybrid plasmid DNA was purified by cesium chlorideethidium bromide density gradient centrifugation for characterization and transformation into the minicellproducing strain.
The transposition element Tn7, a 9-megadalton (Mdal) element deterniining trimethoprim and streptomycin resistance, was found originally in the R plasmid R483 which specifies a type I reductase (3). Plasmid ColEl::Tn7 was constructed by the transposition of Tn7 from plasmid R483 to ColE1 (5) .
Isolation and labeling of minicells. Minicells were isolated by the method of Kool et al. (16) as modified by Dougan and Sherratt (9) . Minicells from 18-h cultures were purified by banding on 5 to 20% linear sucrose gradients and suspended in 1 ml of labeling medium in which methionine assay medium (Difco) was substituted for a synthetic amino acid mix.
After incubation at 370C for 20 Construction of hybrid plasmids. In the present study, derivatives of ColEl::Tn7 were generated by digesting plasmid ColEl::Tn7 and pBR322 DNA with EcoRI and ligating this mixture of fragments. Two hybrid plasmid species were isolated and characterized. One type, for example, plasmid pFE504 (Fig. 1A) , consisted of a 4.7-Mdal ColE1::Tn7 fragment inserted in the EcoRI site of plasmid pBR322. The other plasmids, from transformants selected on agar containing trimethoprim only, each had a single 4.7-Mdal fragment from plasmid ColEl::Tn7 (Fig.  1A , plasmid pFE506).
Plasmid R67, resistant to ampicillin, streptomycin, trimethoprim, chloramphenicol, sulfamethoxazole, and tetracycline (1), was the source of the type II DHFR DNA sequences. The R67 reductase gene located on a 6.5-Mdal EcoRI fragment, was inserted into the EcoRI site of pBR322 ( Fig 1B; plasmid pFE332 ). Specific DNA sequences were deleted from plasmid pFE332 by digesting the DNA with BamHI and ligating the cleavage products. Plasmid pFE364, isolated from a trimethoprim-resistant derivative, lacked two of the plasmid pFE332 BamHI fragments (Fig. 1B, pFE364 ).
An analogous series of hybrid plasmids was constructed using the same 6.5-Mdal EcoRI R67 fragment inserted in the plasmid pSC101 ( Fig.  1; pFE413) . Plasmids pFE425 and pFE420 were constructed by deleting BamHI fragments from pFE413 by the technique described for plasmid pFE364. Both plasmids lacked the largest BamHI fragment of R67. Plasmid pFE420 had a further deletion and was comprised of the 1.6-Mdal BamHI fragment of plasmid R67 and pSC101 DNA sequences (Fig. 1) .
The trimethoprim-resistant DHFR ofplasmid R388 resided in the hybrid plasmid pFE373 (Fig.  10) . It was constructed by inserting a 1.3-Mdal BamHI fragment from R388 into the cloning vector pBR322.
Synthesis of proteins in minicelis. We studied the synthesis of a type II plasmid-encoded DHFR in minicells using the hybrid plasmids derived from R67 (Fig. 1B) . The polypeptides synthesized in minicells containing these plasmids are illustrated in Fig. 2 and 3 . The cloning vehicle pBR322 specified the synthesis of several proteins (Fig. 2D) . The most prominent bands corresponded to ,B-lactamase proteins with molecular weights of 32,000, 30,000, and 27,000. Plasmid pFE364 specified, in addi- Figure 2C and C'). The prime designations for A and C (Fig. 2) indicate the presence of 5 ,Ag of trimethoprim per ml during protein synthesis. The large protein of molecular weight 44,000 was presumably of bacterial origin, since it is synthesized in minicells containing no plasmid DNA.
The plasmids pFE413 and pFE420 contain the R67 reductase gene cloned into pSC101. Both of these hybrid plasmids specified a protein of molecular weight 9,000 ( Fig. 2A, A', and B) . Proteins that comigrated with the fi-lactamase proteins were also synthesized by minicells harboring plasmid pFE413 (Fig. 2B and 3B) . The ,Blactamase proteins were not synthesized by plasmid pFE420 ( Fig. 2A and A'; Fig. 30 ). The production of f,-lactamase proteins by minicells containing plasmid pFE425 (Fig. 3A) and pFE413, but not pFE420, indicated that the R67 fi-lactamase structural gene lies on the 1.3-Mdal BamHI fragment present in pFE425 but deleted from pFE413 in the construction of pFE420.
It is easier to visualize the novel proteins encoded by the R67 (pSC101) hybrids in Fig. 3 . Minicells containing pSC101 synthesized at least six proteins, visible as faint bands in Fig. 3D . Plasmid pFE420 encoded most of the pSC101 proteins (the 29,000 species appeared erproduced) and a rather large amou 9,000 protein (Fig. 3C) Fig. 3F and G. Plasmid amide gel. pBR322-encoded proteins are shown in well 3E. film for 4 Plasmid pFE504 clearly directed the synthesis ) and (C) of fi-lactamase as well as a polypeptide with a molecular weight of 18,000 (Fig. 3F) . The cloning vehicle, pBR322, specified a polypeptide of approximately 16,900 ( Fig. 2D and 3E) , which was Kdaltons close to the molecular weight of the smaller polypeptide synthesized by pFE504. However, the pattern seen in Fig. 3G supports the argument that these are indeed separate and unre---30-0 lated polypeptides. Two major polypeptides of |--30 0 molecular weight 30,000 (presumably the streptomycin-modifying enzyme [4] ) and 18,000 were Type I synthesized by minicells carrying pFE506 (Fig.   16.9 3G). As can be seen in Fig. 1A , plasmid pFE506 144 contains no pBR322 DNA sequences; however, -8 2 pFE506 encodes as much of the 18,000-molecu- 6 2 lar-weight proteins as does pFE504. We conclude from the minicell data presented in Fig. 3 (es synthe-that the type I (R483) DHFR has a molecular ,boring the weight of 18,000 in denaturing gels, whereas the pHFR and type II (R67) DHFR has a molecular weight of ;-polyacryl-9,000. O an X-ray Proof of subunit structure using specific 'C)pFE420; antibody. To definitively show that the 9,000 22, cloning polypeptide encoded by the R67 EcoRI fragment was related to the type II resistant reductase, the following experiment was performed. to be ov-Antibody raised against purified type II enzyme mt of the in rabbits was added to the mixture of labeled 425 speci-polypeptides synthesized in minicells harboring n to those the cloned type II DHFR structural gene. 00 protein Enough formalinized S. aureus cells were then k). There-added to bind all the immunoglobulin G present Ve to the in the reaction mixture. S. aureus strains rich in y R67: (i) protein A on their outer surfaces bind immunoresistance globulin G nonspecifically through the Fc frag-D separate ment (12) . The staphylococcal cells were pelmaller de-leted, and the resultant protein complexes were Iypeptides denatured and electrophoresed. The polypepfour inde-tides synthesized by plasmid pFE364, which conhe type II tains a 1. Fig. 4 , lane B. Labeled minicell lysate plus antibody was electrophoresed, and the results are shown in Fig. 4 , lane A. Clearly, the specific polypeptide recognized by the anti-DHFR type II antibody was the 9,000 species, the putative reductase subunit. An extremely small fraction of the ,B-lactamase proteins nonspecifically bound the staphylococcal protein A (Fig. 4, lane A; 7 ). An additional control was included in which radiolabeled minicell lysate was added to staphylococci in the absence of anti-DHFR type II antibody. Only a faint band corresponding to a small fraction of the ,B-lactamase protein could be observed when this sample was electrophoresed (data not shown).
We also analyzed the resistant DHFR specified by plasmid R388 (2). This particular reductase has a 50% inhibitory concentration for trimethoprim of at least 5,700 ,iM; however, its classification as either a type I or type II DHFR is uncertain (S. Smith, personal communication). The hybrid plasmid pFE373 contains the trimethoprim-resistant reductase originally harbored by R388 (Fig. 1) . Labeled extracts derived from minicells containing pFE373 were reacted with anti-type II DHFR antibody. A polypeptide with a molecular weight of approximately 10,500 reacted specifically with the anti-type II DHFR (R67) antibody (results not shown). In addition, radiolabeled polypeptides, synthesized in minicells harboring the type I reductase derived from Tn7, and R34, a type I DHFR-specifying R plasmid (19) , were reacted with the purified antitype II DHFR antibody. There appeared to be no cross-reactivity between these two type I reductases and the anti-type II DHFR (R67) antibody.
Finally, minicells containing the cloned trimethoprim resistance DHFR gene of the transposition element Tn4O2 directed the synthesis of a 9,000 polypeptide that was specifically precipitated by anti-type II DHFR antibody (Fig. 40) .
The hybrid plasmid pQRS272, containing the trimethoprim-resistant DHFR from transposon Tn402 of R751, was constructed by Roxanne Laux, Tom Petes, and James Shapiro from pBR322 and a HindIII fragment of A imm434 ctsl b515 b519 S7::Tn4O2 (20) . Hence, the reductase situated within Tn402 is related to the type II DHFR specified by naturally occurring R plasmid, R67. (22, 22a) .
DISCUSSION
A possible source of the plasmid-borne determinants is T4 bacteriophage-specified DHFR. (23) recently have compared four R plasmid-encoded reductases by using techniques including gel electrophoresis, analog inhibition proffles, heat sensitivity, and pH optimum curves. They conclude that the DHFRs specified by plasmids R483, R751, and R388 could be "clearly discerned as separate enzymes." These workers did not give subunit molecular weights for the enzymes they studied, and therefore direct comparisons with this study cannot be made. Zolg et al. have reported that the R388-encoded DHFR migrates in SDS-acrylamide gels as an 8,000 polypeptide (25) . The difference between their reported value and our value of 10,500 may be attributable to the substantial error in determining the molecular weights of small polypeptides by this method. We interpret the small but consistent difference observed between the R388 and R67 proteins to mean that the R388 reductase differs from the R67-encoded DHFR in subtle biochemical respects, although antigenically the two enzymes are related.
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